From the Stouffville (Ont.) Sun Tribune:
Helen Gaidatsis will not use Herceptin, Navelbine or Taxotere, the new intravenous cancer drugs the province is now spending $148 million over three years to fund.
But the retired York elementary school principal and breast cancer survivor knows the decision to fund three expensive cancer drugs previously available only through private health insurance or personal expense will held many patients, both medically and financially. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment